Mankind Pharma Board of Directors

Get the latest insights into the leadership at Mankind Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Ramesh Juneja Chairman & Wholetime Director
Mr. Rajeev Juneja Vice Chairman & Mng.Director
Ms. Sheetal Arora Whole Time Director
Mr. Satish Kumar Sharma Whole Time Director
Mr. Vivek Kalra Independent Director
Mr. Tilokchand Punamchand Ostwal Independent Director
Mr. Bharat Anand Independent Director
Ms. Vijaya Sampath Independent Director

Mankind Pharma Share price

MANKIND

2568.9

9.80 (0.38%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:49 IST
BUYSELL
Today's High

2610.10

Today's Low

2563.20

52 Week Low

2115.10

52 Week High

3054.80

The current prices are delayed, login to your account for live prices

Mankind Pharma FAQs

The board at Mankind Pharma consists of experienced professionals, including Mr. Ramesh Juneja , Mr. Rajeev Juneja , and others, overseeing the company’s strategic and corporate governance.

Directors at Mankind Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Ramesh Juneja is the current chairman at Mankind Pharma.

Executive directors at Mankind Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Mankind Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Mankind Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.